Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Prognostic markers in resected stage I and II non small-cell lung cancer: an analysis of 260 patients with 5 year follow-up.

Mehdi SA, Tatum AH, Newman NB, Gamble GP, Etzell JE, Weidner N, Kern JA, Sorscher SM, Kohman LJ, Graziano SL.

Clin Lung Cancer. 1999 Aug;1(1):59-67; discussion 68-9.

PMID:
14725752
2.

Impact of tumor size on survival in stage IA non-small cell lung cancer: a case for subdividing stage IA disease.

Gajra A, Newman N, Gamble GP, Abraham NZ, Kohman LJ, Graziano SL.

Lung Cancer. 2003 Oct;42(1):51-7.

PMID:
14512187
3.

Effect of number of lymph nodes sampled on outcome in patients with stage I non-small-cell lung cancer.

Gajra A, Newman N, Gamble GP, Kohman LJ, Graziano SL.

J Clin Oncol. 2003 Mar 15;21(6):1029-34.

PMID:
12637467
4.

The predictive value of neuroendocrine markers and p53 for response to chemotherapy and survival in patients with advanced non-small cell lung cancer.

Gajra A, Tatum AH, Newman N, Gamble GP, Lichtenstein S, Rooney MT, Graziano SL.

Lung Cancer. 2002 May;36(2):159-65.

PMID:
11955650
5.

Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer.

Graziano SL, Gamble GP, Newman NB, Abbott LZ, Rooney M, Mookherjee S, Lamb ML, Kohman LJ, Poiesz BJ.

J Clin Oncol. 1999 Feb;17(2):668-75.

PMID:
10080613
6.

The prognostic significance of neuroendocrine markers and carcinoembryonic antigen in patients with resected stage I and II non-small cell lung cancer.

Graziano SL, Tatum AH, Newman NB, Oler A, Kohman LJ, Veit LJ, Gamble GP, Coleman MJ, Barmada S, O'Lear S.

Cancer Res. 1994 Jun 1;54(11):2908-13.

Supplemental Content

Loading ...
Support Center